Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Resultados 1 - 20 de 37
Filtrar
1.
J Am Coll Cardiol ; 5(6): 1457-63, 1985 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-2582017

RESUMEN

Ten patients suffering from chronic premature ventricular complexes (greater than 60/h) were treated orally in a double-blind crossover study with encainide (50 mg three times a day) and disopyramide (200 mg three times a day), with five 7 day study periods: survey, placebo, encainide or disopyramide, washout placebo and disopyramide or encainide. At the end of each 7 day period, a 12 lead electrocardiogram, a 48 hour ambulatory electrocardiogram and a treadmill exercise test were performed. Blood levels of encainide and its metabolites and of disopyramide were measured at the end of each treatment (steady state). Drug efficacy was assessed by: 1) more than 80% reduction in the number of premature ventricular complexes per 24 hours, and 2) absence of ventricular tachycardia. Encainide was effective in four patients (complete suppression of premature ventricular complexes) and ineffective in five. One patient who showed a 92% reduction in the number of premature ventricular complexes developed sustained ventricular tachycardia after 24 hours of treatment. Disopyramide was effective in three patients (greater than 80% reduction in the number of premature ventricular complexes) and ineffective in seven patients. With encainide, the percent increase in PR, QRS and QT interval duration was, respectively: 32.7 (p less than 0.001), 30.8 (p less than 0.001) and 10.6% (p less than 0.01). With disopyramide this increase was not significant. Despite the variability of drug blood levels, a relation between blood levels and suppression of premature ventricular complexes on the 48 hour ambulatory electrocardiogram was found with encainide, but not with disopyramide.(ABSTRACT TRUNCATED AT 250 WORDS)


Asunto(s)
Anilidas/uso terapéutico , Antiarrítmicos/uso terapéutico , Arritmias Cardíacas/tratamiento farmacológico , Disopiramida/uso terapéutico , Administración Oral , Adolescente , Adulto , Anciano , Anilidas/administración & dosificación , Anilidas/sangre , Antiarrítmicos/administración & dosificación , Antiarrítmicos/sangre , Arritmias Cardíacas/fisiopatología , Complejos Cardíacos Prematuros/tratamiento farmacológico , Complejos Cardíacos Prematuros/fisiopatología , Ensayos Clínicos como Asunto , Disopiramida/administración & dosificación , Disopiramida/sangre , Método Doble Ciego , Electrocardiografía , Encainida , Prueba de Esfuerzo , Femenino , Humanos , Masculino , Persona de Mediana Edad , Placebos
2.
Am J Psychiatry ; 149(5): 647-50, 1992 May.
Artículo en Inglés | MEDLINE | ID: mdl-1349458

RESUMEN

OBJECTIVE: Beta-blocking agents, particularly propranolol, are considered effective in the treatment of neuroleptic-induced akathisia, but considerable controversy exists about the involved receptor subtype(s). The authors conducted a randomized, controlled trial comparing the effects of propranolol and betaxolol to determine whether central beta 1-adrenoceptor blockade is sufficient to correct neuroleptic-induced akathisia. METHOD: The subjects were 19 patients whose neuroleptic-induced akathisia responded to 20 mg/day of propranolol and subsequently reemerged during a placebo washout period. They were randomly assigned to propranolol (20 or 40 mg/day) or betaxolol (10 or 20 mg/day) and, after another placebo period, were switched to the second beta blocker. RESULTS: There was no significant difference in the antiakathisia effects of propranolol and betaxolol. CONCLUSIONS: The lack of difference between propranolol and betaxolol suggests that beta 1-adrenoceptor blockade is sufficient to improve neuroleptic-induced akathisia. The results of this explanatory study need therapeutic confirmation.


Asunto(s)
Antipsicóticos/efectos adversos , Betaxolol/uso terapéutico , Propranolol/uso terapéutico , Agitación Psicomotora/tratamiento farmacológico , Adulto , Acatisia Inducida por Medicamentos , Método Doble Ciego , Humanos , Persona de Mediana Edad , Placebos
3.
Am J Cardiol ; 52(3): 230-3, 1983 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-6346853

RESUMEN

This study determines, with quantitative variables, if propranolol is detrimental in patients with documented coronary arterial spasm and if this drug can be used in combination with calcium antagonists. Eleven patients with documented coronary spasm were entered prospectively in a study with 4 phases of 2 days each: (1) control, (2) diltiazem or propranolol (mean 225 +/- 75 mg/day), (3) propranolol or diltiazem (360 mg/day), (4) propranolol and diltiazem. The effects of the drugs were assessed by the detection of ischemic electrocardiographic episodes (24-hour electrocardiographic monitoring) and provocative tests with ergonovine. During the period of treatment with propranolol, the number and the duration of attacks increased and provocative tests had positive results in all patients. Diltiazem completely abolished spontaneous episodes, but 6 of 11 patients remained sensitive to the administration of ergonovine. The association of the 2 drugs led to a disappearance of ischemic episodes. In conclusion, propranolol is ineffective in patients with coronary artery spasm. It can be used in combination with diltiazem, but without any advantage over diltiazem alone.


Asunto(s)
Benzazepinas/administración & dosificación , Vasoespasmo Coronario/tratamiento farmacológico , Diltiazem/administración & dosificación , Propranolol/administración & dosificación , Adulto , Anciano , Ensayos Clínicos como Asunto , Quimioterapia Combinada , Femenino , Humanos , Masculino , Persona de Mediana Edad , Distribución Aleatoria
4.
Br J Pharmacol ; 95(4): 1063-74, 1988 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-2851356

RESUMEN

1. LND 623 and LND 796 are two aminosteroid derivatives which exert similar positive inotropic effects to digitalis. Their electrophysiological, toxic and inotropic effects were investigated in both normal and partially K+-depolarized ventricular muscle. 2. In guinea-pig myocardial fibres, LND 623 and LND 796 required tenfold higher concentrations than digoxin to induce the same signs of toxicity; e.g. triggered activities generated from delayed afterdepolarizations, leading to the marked depression of action potential characteristics and inexcitability. These abnormal rhythms and delayed afterdepolarizations were abolished by 1 mM caffeine. The toxic effects were reversed by washout, particularly in the case of LND 796. 3. In normal-K+ solution, LND 623 and LND 796 exhibited concentration-dependent positive inotropic effects on guinea-pig papillary muscle and increased concomitantly resting membrane potential and action potential amplitude. The range of active concentrations (0.1 to 1 microM) of LND 623 was larger than that of digoxin (0.3 to 1 microM). Like digoxin, LND 796 exerted negative inotropic effects at the lowest concentrations (0.01 to 0.03 microM) and positive inotropic effects at high concentrations (1 and 3 microM). 4. In partially K+-depolarized papillary muscle, in the presence of 2 microM histamine, LND 623 (3 and 10 microM) and LND 796 (10 and 30 microM) enhanced the two components P1 and P2 of the contraction and increased slow action potential amplitude, resting potential and maximal rate of depolarization. Low concentrations (0.03 to 0.3 microM) of LND 796 induced negative inotropic effects. beta-Adrenoceptor blockade with atenolol (1 microM) did not modify the activity of LND 623 but significantly enhanced the negative inotropic effect on P2 induced by 1 and 3 microM LND 796 and reduced the positive inotropic effect on P1 and P2 of the highest concentration (30 microM) studied. 5. In the presence of either caffeine (1 mM) or Ca2+-free, Sr2+-rich (3.6 mM) solution, LND 623 and LND 796 produced a positive inotropic effect which was stronger with LND 623. 6. It is suggested that two mechanisms are involved in the inotropic effects of these aminosteroids: (i) an enhanced Ca2 + entry via the slow calcium channels partially brought about by a local release of endogenous catecholamines in the case of LND 796, (ii) an inhibitory effect on Na+-K+ ATPase which, at the highest concentrations, lead to similar signs of cellular toxicity to those described for digitalis drugs. Because of their enlarged positive inotropic range, both aminosteroids may be of interest in the treatment of congestive heart failure.


Asunto(s)
Cardiotónicos/farmacología , Glicósidos/farmacología , Corazón/efectos de los fármacos , Manósidos/farmacología , Pregnanos/farmacología , Animales , Calcio/metabolismo , Electrofisiología , Femenino , Cobayas , Corazón/fisiología , Técnicas In Vitro , Masculino , Contracción Miocárdica/efectos de los fármacos , Músculos Papilares/efectos de los fármacos , Músculos Papilares/fisiología , ATPasa Intercambiadora de Sodio-Potasio/metabolismo , Esteroides
5.
Br J Pharmacol ; 117(7): 1377-9, 1996 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-8730728

RESUMEN

Cisapride, a gastrointestinal prokinetic agent, has been associated with cases of Torsades de Pointes but its effects on the cardiac action potential have not been described. We investigated its electrophysiological effects on rabbit isolated Purkinje fibres. The results demonstrated that cisapride (0.01-10 microM) lengthened concentration-dependently the action potential duration without modifying other parameters and induced early after depolarizations and subsequent triggered activity. This typical class III antiarrhythmic effect, that showed "reverse" rate-dependence and was reduced by increasing external K concentration, can account for clinical arrhythmogenesis.


Asunto(s)
Antiarrítmicos/farmacología , Piperidinas/farmacología , Ramos Subendocárdicos/efectos de los fármacos , Potenciales de Acción/efectos de los fármacos , Animales , Arritmias Cardíacas/fisiopatología , Cisaprida , Electrofisiología , Corazón/efectos de los fármacos , Potasio/farmacología , Ramos Subendocárdicos/fisiopatología , Conejos , Torsades de Pointes/fisiopatología
6.
Am J Clin Pathol ; 96(2): 243-7, 1991 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-1713741

RESUMEN

Formalin-fixed, paraffin-embedded tissue sections from 45 patients with mammary and extramammary Paget's disease were stained immunohistochemically with the use of a polyclonal antiserum directed against a 14-amino acid segment of the c-erbB-2 oncoprotein. Positive membrane staining, which correlates with gene amplification, was found in 15 of 19 cases (79%) of mammary Paget's disease, 4 of 13 cases (31%) of vulvar Paget's disease, none of 8 cases of scrotal Paget's disease, and none of 5 cases of perianal Paget's disease. Of the 19 patients with mammary Paget's disease, specimens of underlying breast tissue were available from 14; all contained a concurrent ductal adenocarcinoma. Concordance of c-erbB-2 antigen staining between the underlying breast carcinoma and the pagetoid component was observed in 12 cases. Of the 13 patients with vulvar Paget's disease, 2 had superficial stromal invasion, and 3 had underlying, deeply invasive adenocarcinomas. One superficially invasive case was positive for c-erbB-2 expression. One additional case of vulvar Paget's disease had an associated primary pagetoid endocervical adenocarcinoma that spread into the endometrium; both the endocervical and vulvar components stained positively for the c-erbB-2 antigen. The results of this study indicate that the c-erbB-2 oncoprotein may play a role in the pathogenesis of extramammary Paget's disease. These results also suggest that the c-erbB-2 oncoprotein may function in vivo to promote intraepithelial spread of adenocarcinoma cells.


Asunto(s)
Enfermedad de Paget Extramamaria/metabolismo , Enfermedad de Paget Mamaria/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Adenocarcinoma/metabolismo , Canal Anal , Femenino , Neoplasias de los Genitales Masculinos/metabolismo , Humanos , Inmunohistoquímica , Ganglios Linfáticos/metabolismo , Metástasis Linfática , Masculino , Enfermedad de Paget Extramamaria/patología , Enfermedad de Paget Mamaria/patología , Receptor ErbB-2 , Escroto , Neoplasias Cutáneas/metabolismo , Coloración y Etiquetado , Neoplasias del Cuello Uterino/metabolismo , Neoplasias de la Vulva/metabolismo
7.
J Appl Physiol (1985) ; 79(6): 2035-42, 1995 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-8847271

RESUMEN

Tissues maintain O2 consumption (VO2) when blood flow and O2 delivery (DO2) are decreased by better matching of blood flow to meet local cellular O2 demand, a process that increases extraction of available O2. This study tested the hypothesis that ATP-sensitive K+ channels play a significant role in the response of pig hindlimb to ischemia. We pump perfused the vascularly isolated but innervated right hindlimb of 14 anesthetized pigs with normoxic blood while measuring hindlimb DO2, VO2, perfusion pressure, and cytochrome aa3 redox state. In one-half of the pigs, the pump-perfused hindlimb was also infused with 10 micrograms.min-1.kg-1 of glibenclamide, a potent blocker of ATP-sensitive K+ channels. Control animals were infused with 5% glucose solution alone. Blood flow was then progressively reduced in both groups in 10 steps at 10-min intervals. Glibenclamide had no effect on any preischemic hindlimb or systemic measurements. Hindlimb VO2 and cytochrome aa3 redox state began to decrease at a significantly higher DO2 in glibenclamide-treated compared with control pigs. At this critical DO2, the O2 extraction ratio (VO2/DO2) was 53 +/- 4% in the glibenclamide group and 73 +/- 5% in the control group (P < 0.05). Hindlimb vascular resistance increased significantly with ischemia in the glibenclamide group but did not change in the control group. We conclude that ATP-sensitive K+ channels may be importantly involved in the vascular recruitment response that tried to meet tissue O2 needs as blood flow was progressively reduced in the pig hindlimb.


Asunto(s)
Adenosina Trifosfato/farmacología , Miembro Posterior/fisiopatología , Isquemia/fisiopatología , Oxígeno/metabolismo , Canales de Potasio/efectos de los fármacos , Animales , Hemodinámica/fisiología , Consumo de Oxígeno , Porcinos , Resistencia Vascular
8.
Fundam Clin Pharmacol ; 8(5): 391-407, 1994.
Artículo en Inglés | MEDLINE | ID: mdl-7875633

RESUMEN

Cardiac arrhythmias and sudden death have been associated with both therapeutic and toxic doses of a number of cardiotropic and non-cardiac drugs. Generally the drug-induced electrocardiographic (ECG) alterations have been well described, whereas corresponding cellular electrophysiological effects are poorly documented or lacking. Taking into account the recent advances in the understanding of the mechanisms underlying arrhythmias and antiarrhythmic effects, suitable relationships can be established between ECG alterations and drug effects on cardiac action potential. Thus, a decrease in maximal upstroke velocity (Vmax) and membrane depolarisation leading to cellular inexcitability may slow conduction, prolong QRS interval duration and result in incessant wide QRS ventricular tachycardia. On the other hand, lengthening of the repolarisation phase and early afterdepolarisations (EADs) have been proposed as a mechanism for prolonged QT interval and subsequent Torsades de Pointes. A representative study aimed at detecting the arrthymogenic potentiality of a drug is given, by examining carefully the concentration- and frequency-dependent effects of four neuroleptics (sultopride, droperidol, thioridazine and clozapine) on Purkinje fibers and comparing them with the reported iatrogenic arrhythmias. The results showed that 10 to 100 microM sultopride and 0.01 to 1 microM droperidol exerted "pure" class III effects. In addition, higher concentrations (3 to 30 microM) of droperidol reversed the prolonging effect on repolarisation concomitantly with a dose- and frequency-dependent decrease in Vmax, action potential amplitude and resting membrane potential (class I effects) resulting in cellular inexcitability at 30 microM. Similar class I effects were induced by thioridazine and clozapine concomitantly with a slight prolonging effect on final repolarisation (class Ia effects). In the presence of sultopride (30 and 100 microM) and droperidol (0.3 to 3 microM), EADs developed at plateau level. Their incidence, amplitude and number were influenced by extracellular K or Mg concentration, stimulation frequency, modification of Ca entry (by nifedipine or isoproterenol). These experimental results fit well with clinical data although they need further development to precise underlying ionic mechanisms. Therefore, in vitro studies should be considered before clinical prospects for future drug development.


Asunto(s)
Arritmias Cardíacas/inducido químicamente , Animales , Arritmias Cardíacas/fisiopatología , Electrocardiografía/efectos de los fármacos , Electrofisiología/métodos , Humanos , Enfermedad Iatrogénica , Técnicas In Vitro
9.
Fundam Clin Pharmacol ; 6(3): 113-21, 1992.
Artículo en Inglés | MEDLINE | ID: mdl-1321090

RESUMEN

Overdose cardiac effects of imipramine are due to fast Na channel blockade and are clinically reversed by administration of sodium lactate which induces alkalosis (about pH 7.50) and hypernatremia (about 8 mM). The mechanisms of this beneficial effect of Na lactate were explored in vitro on guinea-pig ventricular myocardium using the microelectrode technique. The time-course effects of the clinically relevant concentration of 10 microM imipramine on action potential characteristics were examined at pH 7.20 and pH 7.50. To test whether alkalinisation per se is important or whether an increase in Na concentration plays a major role in the reversal effect, preparations were exposed to increasing concentrations (1, 3, 10, 30, 100 mM) of either Na lactate, bicarbonate or chloride in the absence or in the presence of 10 microM imipramine at pH 7.50. The influence of elevating osmolality was evaluated with equivalent concentrations of sucrose. Imipramine alone significantly depressed Vmax and shortened action potential duration at all phases of repolarisation. All three high sodium solutions reversed imipramine effects. However the reversal effect was already obvious with 10 mM Na lactate and 10 mM NaHCO3 but not 10 mM NaCl. Osmolality did not reverse the imipramine-induced Vmax depression. The results suggest that at the clinically relevant 10 mM concentration, sodium lactate and bicarbonate may displace imipramine from its receptor site on the Na channel by causing alkalosis at the membrane level without profoundly affecting the driving force of the Na current, whereas at the upper concentrations, the increase in Na ion concentrations is predominantly involved in the reversal of imipramine effects.


Asunto(s)
Potenciales de Acción/efectos de los fármacos , Imipramina/antagonistas & inhibidores , Lactatos/farmacología , Miocardio/química , Animales , Bicarbonatos/farmacología , Femenino , Cobayas , Ventrículos Cardíacos/efectos de los fármacos , Concentración de Iones de Hidrógeno , Imipramina/farmacología , Ácido Láctico , Masculino , Concentración Osmolar , Sodio/farmacología , Bicarbonato de Sodio , Cloruro de Sodio/farmacología
10.
Fundam Clin Pharmacol ; 3(3): 237-44, 1989.
Artículo en Inglés | MEDLINE | ID: mdl-2767606

RESUMEN

Midalcipran is a new antidepressant drug inhibiting both noradrenaline and serotonin uptake without any postsynaptic and anticholinergic activities. Its cardiac effects were compared with those of imipramine, a tricyclic antidepressant drug. In anaesthetised guinea-pigs intravenous perfusion of imipramine and midalcipran (1 ml/min from a solution at 0.66 mg/ml) brought about ventricular arrhythmias, respectively at 16.5 and 26.4 mg/kg and cardiac arrest at 58 and 97 mg/kg. The safety index (ratio of i.v. lethal dose and ED50 evaluated by the yohimbine test) is 22 times wider for midalcipran than imipramine. In in vitro studies on guinea-pig ventricular myocardium, imipramine exerted a greater class 1 antiarrhythmic effect than midalcipran. The reduction of Vmax was significant at 3 X 10(-6) M for imipramine and 1 X 10(-5) M for midalcipran in normal (4 mM K+) and hyperpolarizing (2.7 mM K+) conditions. At the concentration of 1 X 10(-5) M midalcipran significantly lengthened, whereas imipramine non significantly shortened the action potential durations (APD50, APD90). The results provide confirmation of a lesser depression in sodium conductance with midalcipran as compared to imipramine. Therefore it is proposed that less adverse cardiac effects may be observed at therapeutic doses.


Asunto(s)
Antidepresivos/farmacología , Ciclopropanos/farmacología , Corazón/efectos de los fármacos , Imipramina/farmacología , Potenciales de Acción/efectos de los fármacos , Animales , Electrofisiología , Femenino , Cobayas , Técnicas In Vitro , Infusiones Intravenosas , Masculino , Potenciales de la Membrana/efectos de los fármacos , Milnaciprán , Contracción Miocárdica/efectos de los fármacos , Músculos Papilares/efectos de los fármacos , Potasio/farmacología
11.
Clin Cardiol ; 11(7): 454-60, 1988 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-2970904

RESUMEN

At the present time, there is no satisfactory pharmacological treatment for arrhythmia or conduction disorders induced by or aggravated by vagal hypertonia. The limited duration of action of the atropine derivatives currently available justifies the development of new compounds with expected longer acting duration. The aim of this study was to compare the effects of a single blind intravenous injection of ipratropium bromide to those of atropine sulfate in 22 patients. These patients were studied with continuous Holter recordings for three days. During the second and the third nights (patient sleeping), boluses of atropine (0.03 mg/kg) and of ipratropium bromide (0.03 mg/kg), respectively, were added to a continuous saline intravenous infusion. Accurate ECG analysis allowed determination of maximal heart rate peak, timing of maximal heart rate, variations in sinus cycle length, atrioventricular conduction, and durations of drug action. A nonsuggestive questionnaire was presented to patients to detect possible occurrence of side effects. The mean maximal heart rate rose significantly (p less than 0.001) for atropine (+46.2%) and for ipratropium bromide (+57.4%). The effects obtained with ipratropium bromide on the heart rate lasted nearly twice as long as those obtained with atropine (respectively, 120 +/- 38.4 min and 70 +/- 30 min- for the pharmacological half-life). Common minor muscarinic side effects (dryness of the mouth) were noted with the two drugs. In conclusion, this comparative intraindividual study confirmed the prolonged vagolytic effects of intravenous ipratropium bromide, which may be valuable in the treatment of patients with vagally mediated automaticity and conduction disturbances.


Asunto(s)
Derivados de Atropina/administración & dosificación , Atropina/administración & dosificación , Frecuencia Cardíaca/efectos de los fármacos , Ipratropio/administración & dosificación , Adulto , Atropina/efectos adversos , Atropina/farmacología , Electrocardiografía , Femenino , Semivida , Humanos , Inyecciones Intravenosas , Ipratropio/efectos adversos , Ipratropio/farmacología , Masculino , Persona de Mediana Edad , Monitoreo Fisiológico
12.
Eur Psychiatry ; 14(2): 93-100, 1999 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-10572333

RESUMEN

The goal of this prospective investigation was to study the course and the quality of patient-psychiatrist relationships during phase II / phase III clinical trials of antidepressant medication prescribed for depressive disorders. All patients who participated in the clinical trials (and subsequently in this survey) signed written informed consent statements and were subject to random double blind treatment assignment. Retrospective analysis of 118 investigations was carried out, and the patients involved were questioned concerning their experiences and impressions during and after the study. Data show that the outcome of clinical trials of antidepressant drugs are not a function of pre-existing good patient-psychiatrist relationships. On the other hand, no effects on the patient-psychiatrist relationship were found as a result of the experimental procedure, and it can be concluded that no detrimental effects on future patient-psychiatrist relationships were incurred.


Asunto(s)
Trastorno Depresivo Mayor/tratamiento farmacológico , Relaciones Médico-Paciente , Adulto , Trastorno Depresivo Mayor/diagnóstico , Método Doble Ciego , Femenino , Humanos , Masculino , Satisfacción del Paciente , Estudios Prospectivos , Escalas de Valoración Psiquiátrica , Estudios Retrospectivos
13.
Acta Cytol ; 35(2): 215-20, 1991.
Artículo en Inglés | MEDLINE | ID: mdl-1709323

RESUMEN

In order to assess the utility of immunocytochemical staining of bile canaliculi with a polyclonal antiserum to carcinoembryonic antigen (pCEA) in the differentiation of primary hepatocellular carcinomas from metastatic malignancies, pCEA staining was performed on fine needle aspiration specimens from hepatic lesions in 60 patients. The original cytologic diagnoses were hepatocellular carcinoma in 22 patients, metastatic neoplasm or cholangiocarcinoma in 27 patients and benign hepatocytes in 11 cases. The cytologic diagnoses of malignancy were confirmed by surgical excision, autopsy or clinical investigations in 82% of the patients. Follow-up data, supported by pCEA staining, reversed the original cytologic diagnosis in three cases. Bile canalicular pCEA staining was identified in 18 of 22 cases of hepatocellular carcinoma and in all 11 benign hepatocellular aspirates. All 27 cases of metastatic malignancy or cholangiocarcinoma were negative for canalicular pCEA staining, although 11 cases exhibited cytoplasmic staining. Interpretation of pCEA staining was not affected by the intermingling of malignant cells and benign hepatocytes. Predictive values were 100% for a positive test and 87% for a negative test. These findings indicate that staining with pCEA antiserum is a useful adjunct in the differential cytologic diagnosis of malignant hepatic lesions.


Asunto(s)
Antígeno Carcinoembrionario/análisis , Neoplasias Hepáticas/diagnóstico , Adenocarcinoma/diagnóstico , Adenocarcinoma/patología , Biopsia con Aguja/métodos , Carcinoma Hepatocelular/diagnóstico , Carcinoma Hepatocelular/patología , Diagnóstico Diferencial , Estudios de Seguimiento , Humanos , Neoplasias Hepáticas/patología , Neoplasias Hepáticas/secundario , Coloración y Etiquetado
14.
Arch Mal Coeur Vaiss ; 83(13): 1921-5, 1990 Nov.
Artículo en Francés | MEDLINE | ID: mdl-2125410

RESUMEN

As with any therapeutic intervention, in the evaluation of medical treatment of chronic cardiac failure, methods of assessing the efficacy of the drug (for example, measuring haemodynamic parameters) have to be distinguished from those designed to show therapeutic benefit (for example, prolongation of survival, quantified improvement in performance without excess mortality or deterioration in the quality of life). Studies of survival are long and costly and, as yet, have been conducted only in advanced stages of the disease. They are difficult to set up before the drug has been approved for general use i.e. when the only indication is the treatment of cardiac failure. If a criterion of substitution is not validated, the evaluation of the effects of the drug on quantified performances remains essential in pilot studies and phase 3 trials despite their artificial appearances. These trials are difficult to coordinate as they are usually multicenter and relatively prolonged (at least 6 months) studies.


Asunto(s)
Evaluación de Medicamentos/métodos , Insuficiencia Cardíaca/tratamiento farmacológico , Enfermedad Crónica , Prueba de Esfuerzo , Hemodinámica/efectos de los fármacos , Humanos , Función Ventricular Izquierda/efectos de los fármacos
15.
Arch Mal Coeur Vaiss ; 74 Spec No: 17-27, 1981 Dec.
Artículo en Francés | MEDLINE | ID: mdl-6803699

RESUMEN

A number of different in vitro or in vivo experimental tests or models are now available for the demonstration of antiarrhythmic properties. In vitro electrophysiological studies on cells or healthy tissues usually establish the properties of antiarrhythmic agents, rather than their actual antiarrhythmic properties. New information has recently been provided by studies on abnormal tissues or tissues which have been made abnormal experimentally. The methods used to cause this dysfunction are discussed to determine their possible clinical relevance. There are over 50 in vivo arrhythmia models but only 2 or 3 are in common usage: aconitine or digitalis intoxication and experimental myocardial infarction (Harris' method and variants). The study of thresholds to ventricular fibrillation is more a study of an electrophysiological parameter than a study of an arrhythmia. Statistical studies require the uniformity of an experimental model and its stability (or relative stability) over a sufficiently long period from one animal or preparation to another. These conditions widen the gap between some experimental models and clinical reality. Present experimental models are essentially models of acute arrhythmias as experimental animals with chronic degenerative heart disease are not usually available (the problem of cardiomyopathic hamsters and Japanese woodcocks is discussed). The failure to appreciate the differences between species, the direct action of the drug under study (particularly on the autonomic nervous system), the hemodynamic changes induced by the experimental conditions, and the pharmacokinetics of the drug, often make extrapolations to clinical practice very difficult. Although the recent advances in our understanding of the mechanisms of arrhythmias derived from these models have not lead to any significant changes in the clinicians' attitude to the choice of antiarrhythmic therapy or to the introduction of new criteria of antiarrhythmic efficacity, none of the active antiarrhythmic agents used in clinical practice have been submitted to these antiarrhythmic screening tests. These models even provide an "honourable" classification of the relative efficacity of antiarrhythmic drugs.


Asunto(s)
Antiarrítmicos/uso terapéutico , Arritmias Cardíacas/tratamiento farmacológico , Modelos Cardiovasculares , Animales , Arritmias Cardíacas/inducido químicamente , Gatos , Coturnix , Cricetinae , Perros , Evaluación Preclínica de Medicamentos , Electrocardiografía , Sistema de Conducción Cardíaco/efectos de los fármacos , Humanos , Infarto del Miocardio/complicaciones , Papio , Ratas , Ovinos , Especificidad de la Especie , Porcinos
20.
J Mol Cell Cardiol ; 18(12): 1287-99, 1986 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-2434659

RESUMEN

The effects of prolonged exposure to combined mild hypoxia (Po2 230 +/- 20 mmHg) and acidosis (pH: 6.8 +/- 0.05) were studied in guinea-pig left ventricular myocardium superfused in vitro. Only Purkinje fibers were impaled by microelectrodes. Triggered activity developed in depolarized Purkinje fibers after 48 +/- 9 min of exposure to hypoxic and acid conditions and was initiated either by short periods of rapid electrical driving or by the background slow Purkinje automaticity. Triggered activity occurred when a delayed afterdepolarization attained its threshold potential and terminated after a subthreshold afterdepolarization. Interaction between triggered activity and slow background automaticity was observed until 90 to 180 min of exposure to hypoxic and acid conditions. These effects were reversed by replacement in standard conditions (Po2 510 +/- 20 mmHg; pH 7.35 +/- 0.05). Norepinephrine (1 X 10(-6)M) significantly accelerated the rate of discharge of triggered foci and led to a stable sustained triggered activity. Increasing extracellular Ca2+ concentration aggravated the effects of combined mild hypoxia and acidosis and led to the occurrence of early afterdepolarizations initiating triggered activity. In addition abnormal automaticity developed in quiescent fibers without any triggering action potential. Lidocaine and verapamil suppressed the triggered activity following a subthreshold afterdepolarization. Their effects were reversed on wash-out. It is concluded that prolonged exposure to combined mild hypoxia and acidosis induces triggered activity by a basic mechanism common to other situations leading to a calcium overload and showing such behaviour.


Asunto(s)
Acidosis/complicaciones , Arritmias Cardíacas/etiología , Sistema de Conducción Cardíaco/fisiopatología , Hipoxia/complicaciones , Ramos Subendocárdicos/fisiopatología , Acidosis/fisiopatología , Animales , Arritmias Cardíacas/tratamiento farmacológico , Arritmias Cardíacas/fisiopatología , Calcio/farmacología , Femenino , Cobayas , Hipoxia/fisiopatología , Técnicas In Vitro , Canales Iónicos/efectos de los fármacos , Canales Iónicos/metabolismo , Lidocaína/farmacología , Masculino , Norepinefrina/farmacología , Ramos Subendocárdicos/efectos de los fármacos , Verapamilo/farmacología
SELECCIÓN DE REFERENCIAS
Detalles de la búsqueda